[1] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015 [J]. CA: a cancer journal for clinicians, 2016, 66(2): 115-32.
[2] Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015 [J]. JAMA oncology, 2017, 3(12): 1683-91.
[3] Bray F, Ferlay J, Soerjomataram I, et al. Cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[4] Forner A, Reig M. Bruix J Hepatocellular carcinoma [J]. Lancet, 2018, 391(10127): 1301-14.
[5] Marrero J A, Kulik L M, Sirlin C B, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases [J]. Hepatology, 2018, 68(2): 723-50.
[6] Yang W S, Stockwell B R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells [J]. Chemistry & biology, 2008, 15(3): 234-45.
[7] Gao M, Monian P, Quadri N, et al. Glutaminolysis and transferrin regulate ferroptosis [J]. Molecular cell, 2015, 59(2): 298-308.
[8] Sun X, Ou Z, Xie M, et al. HSPB1 as a novel regulator of ferroptotic cancer cell death [J]. Oncogene, 2015, 34(45): 5617-25.
[9] Song Y, Yang H, Lin R, et al. The role of ferroptosis in digestive system cancer [J]. Oncology letters, 2019, 18(3): 2159-64.
[10] Xia X, Fan X, Zhao M, et al. The relationship between ferroptosis and tumors: A novel landscape for therapeutic approach [J]. Current gene therapy, 2019, 19(2): 117-24.
[11] Chen G, Guo G, Zhou X, et al. Potential mechanism of ferroptosis in pancreatic cancer [J]. Oncology letters, 2020, 19(1): 579-87.
[12] Li J, Dirisala A, Ge Z, et al. Therapeutic Vesicular Nanoreactors with Tumor‐Specific Activation and Self‐Destruction for Synergistic Tumor Ablation [J]. Angewandte Chemie, 2017, 129(45): 14213-8.
[13] Lin L-S, Huang T, Song J, et al. Synthesis of copper peroxide nanodots for H2O2 self-supplying chemodynamic therapy [J]. Journal of the American Chemical Society, 2019, 141(25): 9937-45.
[14] Louandre C, Ezzoukhry Z, Godin C, et al. Iron‐dependent cell death of hepatocellular carcinoma cells exposed to sorafenib [J]. International journal of cancer, 2013, 133(7): 1732-42.
[15] Yuan H, Li X, Zhang X, et al. CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation [J]. Biochemical and biophysical research communications, 2016, 478(2): 838-44.
[16] Bai T, Wang S, Zhao Y, et al. Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells [J]. Biochemical and biophysical research communications, 2017, 491(4): 919-25.
[17] Sun X, Ou Z, Chen R, et al. Activation of the p62‐Keap1‐NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells [J]. Hepatology, 2016, 63(1): 173-84.
[18] Mages K, Grassmann F, Jägle H, et al. The agonistic TSPO ligand XBD173 attenuates the glial response thereby protecting inner retinal neurons in a murine model of retinal ischemia [J]. Journal of neuroinflammation, 2019, 16(1): 1-16.
[19] Liu Z, Zhao Q, Zuo Z-X, et al. Systematic Analysis of the Aberrances and Functional Implications of Ferroptosis in Cancer [J]. Iscience, 2020, 23(7): 101302.
[20] De Matteis S, Ragusa A, Marisi G, et al. Aberrant metabolism in hepatocellular carcinoma provides diagnostic and therapeutic opportunities [J]. Oxidative medicine and cellular longevity, 2018, 2018(
[21] Angeli J P F, Shah R, Pratt D A, et al. Ferroptosis inhibition: mechanisms and opportunities [J]. Trends in pharmacological sciences, 2017, 38(5): 489-98.
[22] Kagan V E, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis [J]. Nature chemical biology, 2017, 13(1): 81-90.
[23] Krebs K, Böttinger N, Huang L-R, et al. All studies published in Gastroenterology are embargoed until 3PM ET of the day they are published as corrected proofs on-line. Studies cannot be publicized as accepted manuscripts or uncorrected proofs [J]. 2013,
[24] Cho S, Kim S B, Lee Y, et al. Endogenous TLR2 ligand embedded in the catalytic region of human cysteinyl-tRNA synthetase 1 [J]. Journal for Immunotherapy of Cancer, 2020, 8(1):
[25] Wu X-Y, Qian J-J, Lin Y, et al. Hepatitis B virus X protein disrupts DNA interstrand crosslinking agent mitomycin C induced ATR dependent intra-S-phase checkpoint [J]. European journal of cancer, 2008, 44(11): 1596-602.
[26] Palagyi A, Neveling K, Plinninger U, et al. Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents [J]. Molecular cancer, 2010, 9(1): 1-15.
[27] Komatsu H, Masuda T, Iguchi T, et al. Clinical significance of FANCD2 gene expression and its association with tumor progression in hepatocellular carcinoma [J]. Anticancer research, 2017, 37(3): 1083-90.
[28] Guo W, Zhao Y, Zhang Z, et al. Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma [J]. Cancer letters, 2011, 312(1): 55-61.
[29] Lang X, Green M, Wang W, et al. Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11 [J]. Cancer discovery, 2019, 9(12): 1673-85.
[30] Liu T, Jiang L, Tavana O, et al. The deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7A11 [J]. Cancer research, 2019, 79(8): 1913-24.
[31] Yue C, Ren Y, Ge H, et al. Comprehensive analysis of potential prognostic genes for the construction of a competing endogenous RNA regulatory network in hepatocellular carcinoma [J]. OncoTargets and therapy, 2019, 12(561.
[32] Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma [J]. Nature reviews Gastroenterology & hepatology, 2015, 12(12): 681-700.
[33] Tai D, Choo S P, Chew V. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers [J]. Cancers, 2019, 11(12): 1926.
[34] Gopu V, Cai Y, Krishnan S, et al. An accurate aging clock developed from the largest dataset of microbial and human gene expression reveals molecular mechanisms of aging [J]. bioRxiv, 2020,
[35] Finn R, Ryoo B, Merle P, et al. KEYNOTE-240 investigators. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial [J]. J Clin Oncol, 2020, 38(3): 193-202.